These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 4913153)

  • 21. Psychopharmacological studies of lysergic acid diethylamide (LSD-25) intoxication; effects of premedication with BOL-128 (2-bromo-d-lysergic acid diethylamide), mescaline, atropine, amobarbital, and chlorpromazine.
    CLARK LD; BLISS EL
    AMA Arch Neurol Psychiatry; 1957 Dec; 78(6):653-5. PubMed ID: 13478222
    [No Abstract]   [Full Text] [Related]  

  • 22. Phencyclidine, lysergic acid diethylamide, and mescaline: cerebral artery spasms and hallucinogenic activity.
    Altura BT; Altura BM
    Science; 1981 May; 212(4498):1051-2. PubMed ID: 7195070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of cross-tolerance in rats among (-)delta9-trans-tetrahydrocannabinol(delta9-THC), cannabis extract, mescaline and lysergic acid diethylamide (LSD-25).
    Teresa M; Silva A; Carlini EA; Claussen U; Korte F
    Psychopharmacologia; 1968; 13(4):332-40. PubMed ID: 5722169
    [No Abstract]   [Full Text] [Related]  

  • 24. Chromosome studies on patients (in vivo) and cells (in vitro) treated with lysergic acid diethylamide.
    Corey MJ; Andrews JC; McLeod MJ; MacLean JR; Wilby WE
    N Engl J Med; 1970 Apr; 282(17):939-43. PubMed ID: 5436029
    [No Abstract]   [Full Text] [Related]  

  • 25. Psychedelic agents in creative problem-solving: a pilot study.
    Harman WW; McKim RH; Mogar RE; Fadiman J; Stolaroff MJ
    Psychol Rep; 1966 Aug; 19(1):211-27. PubMed ID: 5942087
    [No Abstract]   [Full Text] [Related]  

  • 26. [Critical study on taraxeine].
    Bury JA
    Encephale; 1969; 58(1):69-94. PubMed ID: 4989013
    [No Abstract]   [Full Text] [Related]  

  • 27. CLINICAL SYNDROMES AND BIOCHEMICAL ALTERATIONS FOLLOWING MESCALINE, LYSERGIC ACID DIETHYLAMIDE, PSILOCYBIN AND A COMBINATION OF THE THREE PSYCHOTOMIMETIC DRUGS.
    HOLLISTER LE; SJOBERG BM
    Compr Psychiatry; 1964 Jun; 5():170-8. PubMed ID: 14156873
    [No Abstract]   [Full Text] [Related]  

  • 28. Environmental influences upon drug-induced suppression of operant behavior.
    Sparber SB; Tilson HA
    J Pharmacol Exp Ther; 1971 Oct; 179(1):1-9. PubMed ID: 5096565
    [No Abstract]   [Full Text] [Related]  

  • 29. [Psycho-dysleptics].
    Polvan O
    Turk Tip Cemiy Mecm; 1966 Nov; 32(11):661-70. PubMed ID: 5979072
    [No Abstract]   [Full Text] [Related]  

  • 30. [Experimental contribution to the problem of possible crossed tolerance between psychotic drugs of different structure].
    MISSERE G; TONINI G
    Boll Soc Ital Biol Sper; 1959 Sep; 35():1119-20. PubMed ID: 14422940
    [No Abstract]   [Full Text] [Related]  

  • 31. Cumulative alterations in rat behavior during continuous administration of LSD or mescaline: absence of tolerance?
    Ellison G; Ring M; Ross D; Axelrood B
    Biol Psychiatry; 1980 Feb; 15(1):95-102. PubMed ID: 7357060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Various psychodysleptic substances].
    Bernik V
    Rev Paul Med; 1972 Aug; 80(2):115-7. PubMed ID: 4671580
    [No Abstract]   [Full Text] [Related]  

  • 33. A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist.
    Colpaert FC; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1982 Apr; 221(1):206-14. PubMed ID: 7062283
    [No Abstract]   [Full Text] [Related]  

  • 34. Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures.
    HOLLISTER LE; HARTMAN AM
    Compr Psychiatry; 1962 Aug; 3():235-42. PubMed ID: 13908449
    [No Abstract]   [Full Text] [Related]  

  • 35. [Sensory deprivation and psychodysleptic activity].
    Roche M
    C R Seances Soc Biol Fil; 1970; 164(8):1756-62. PubMed ID: 4253202
    [No Abstract]   [Full Text] [Related]  

  • 36. Hallucinogens and dominance behavior of the rat.
    Uyeno ET
    Proc West Pharmacol Soc; 1967; 10():94. PubMed ID: 6055511
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of LSD, mescaline, and D-amphetamine on the evoked "secondary discharge".
    Roth WT
    Psychopharmacologia; 1966; 9(3):253-8. PubMed ID: 6010545
    [No Abstract]   [Full Text] [Related]  

  • 38. Facilitation of avoidance behaviour by LSD-25 and mescaline in hamsters.
    Sansone M; Castellano C; Messeri P
    Pharmacol Res Commun; 1974 Aug; 6(4):369-76. PubMed ID: 4438404
    [No Abstract]   [Full Text] [Related]  

  • 39. The pharmacology of mescaline and D-lysergic acid diethylamide (LSD).
    KOELLE GB
    N Engl J Med; 1958 Jan; 258(1):25-32. PubMed ID: 13493730
    [No Abstract]   [Full Text] [Related]  

  • 40. Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli.
    Aghajanian GK
    Brain Res; 1980 Mar; 186(2):492-8. PubMed ID: 7357465
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.